289 related articles for article (PubMed ID: 27125958)
21. Medullary Thyroid Carcinoma: Imaging.
Delorme S; Raue F
Recent Results Cancer Res; 2015; 204():91-116. PubMed ID: 26494385
[TBL] [Abstract][Full Text] [Related]
22. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
[TBL] [Abstract][Full Text] [Related]
23. Negative predictive value of procalcitonin in medullary thyroid carcinoma.
Lim SK; Guéchot J; Vaubourdolle M
Ann Biol Clin (Paris); 2016; 74(2):213-8. PubMed ID: 26806393
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels.
Milone F; Ramundo V; Chiofalo MG; Severino R; Paciolla I; Pezzullo L; Lombardi G; Colao A; Faggiano A
Clin Endocrinol (Oxf); 2010 Jul; 73(1):85-8. PubMed ID: 20039894
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
[TBL] [Abstract][Full Text] [Related]
26. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
[TBL] [Abstract][Full Text] [Related]
27. Calcitonin-negative neuroendocrine tumor of the thyroid: a distinct clinical entity.
Chernyavsky VS; Farghani S; Davidov T; Ma L; Barnard N; Amorosa LF; Trooskin SZ
Thyroid; 2011 Feb; 21(2):193-6. PubMed ID: 21275766
[TBL] [Abstract][Full Text] [Related]
28. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract][Full Text] [Related]
29. Other markers of medullary thyroid cancer, not only calcitonin.
Censi S; Manso J; Mian C
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651167
[TBL] [Abstract][Full Text] [Related]
30. Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review.
Karagiannis AK; Girio-Fragkoulakis C; Nakouti T
Anticancer Res; 2016 Aug; 36(8):3803-10. PubMed ID: 27466480
[TBL] [Abstract][Full Text] [Related]
31. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
[TBL] [Abstract][Full Text] [Related]
32. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules.
Giovanella L; Verburg FA; Imperiali M; Valabrega S; Trimboli P; Ceriani L
Clin Chem Lab Med; 2013 Jul; 51(7):1477-81. PubMed ID: 23314540
[TBL] [Abstract][Full Text] [Related]
33. A Rare Case of Negative Serum Calcitonin in Metastatic Medullary Thyroid Carcinoma: Diagnosis, Treatment, and Follow-Up Strategy.
Licata L; Di Fidio CA; Vacante M; Basile F; Biondi A; Richiusa P; Gurrera A; Ciuni R
Am J Case Rep; 2022 Sep; 23():e935207. PubMed ID: 36088532
[TBL] [Abstract][Full Text] [Related]
34. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
[TBL] [Abstract][Full Text] [Related]
35. Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.
Treglia G; Rufini V; Piccardo A; Imperiale A
Semin Nucl Med; 2023 Jul; 53(4):481-489. PubMed ID: 36702731
[TBL] [Abstract][Full Text] [Related]
36. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review.
Trimboli P; Seregni E; Treglia G; Alevizaki M; Giovanella L
Endocr Relat Cancer; 2015 Jun; 22(3):R157-64. PubMed ID: 25934688
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology and Clinical Presentation of Medullary Thyroid Carcinoma.
Raue F; Frank-Raue K
Recent Results Cancer Res; 2015; 204():61-90. PubMed ID: 26494384
[TBL] [Abstract][Full Text] [Related]
38. Novel acquisitions in the diagnosis of medullary thyroid carcinoma.
Trimboli P; Crescenzi A; Saggiorato E; Treglia G; Giovanella L
Minerva Endocrinol; 2017 Sep; 42(3):238-247. PubMed ID: 27808486
[TBL] [Abstract][Full Text] [Related]
39. Ultrasonographic Features of Medullary Thyroid Carcinoma: Do they Correlate with Pre and PostOperative Calcitonin Levels?
Cho KE; Gweon HM; Park AY; Yoo MR; Kim J; Youk JH; Park YM; Son EJ
Asian Pac J Cancer Prev; 2016; 17(7):3357-62. PubMed ID: 27509975
[TBL] [Abstract][Full Text] [Related]
40. Relevance of calcitonin cut-off in the follow-up of medullary thyroid carcinoma for conventional imaging and 18-fluorine-fluorodihydroxyphenylalanine PET.
Sesti A; Mayerhoefer M; Weber M; Anner P; Wadsak W; Dudczak R; Haug A; Karanikas G
Anticancer Res; 2014 Nov; 34(11):6647-54. PubMed ID: 25368270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
